Research & Development
Established Research & Development Platform
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District
Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations
30+
Commercial stage proprietary products
10+
Scientists
7+
Canadian Government research grants awarded since 2020
8+
Pending Patents
4+
Health Canada cannabis R&D licenses issued to Avicanna or its academic collaborators
World Class Institutional Collaborations
R&D and Clinical Partnerships Over the Past 4 Years
World-Class Collaborations
R&D collaborations with world-class academic and clinical institutes
Avicanna counts with collaborations with world-class academic and clinical institutes Including 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.
MaRS Discovery
District
University Health
Network
Hospital of
Sick Children
University of
Guelph
JLABS @ Toronto
University of
Toronto
Sunnybrook Health
Science Centre
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
Pharmaceutical Pipeline
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence
Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization.
These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
